In cases where PTH levels remain elevated without hypercalcemia or an identifiable secondary cause, the condition is termed normocalcemic primary hyperparathyroidism (NPHPT), an increasingly recognized variant that may still confer skeletal and cardiovascular risk [22]. This evidence concerns the gene PTH and hypercalcemia disease.